Massive study of 22 million seniors tests pneumonia Vaccine's Real-World power
NCT ID NCT06782282
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how effective the Prevnar 20 (PCV20) vaccine is at preventing serious lung infections in people aged 65 and older. Researchers will analyze medical records from over 22 million Medicare beneficiaries, comparing those who got the vaccine to those who did not. The goal is to see if the vaccine reduces cases of pneumonia and other lower respiratory infections in real-world conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Prevnar 20 (20-valent pneumococcal conjugate vaccine, PCV20)
What this could lead to
If successful, this could confirm that the PCV20 vaccine effectively prevents serious lung infections in older adults, supporting its widespread use.
What could go wrong
This is an observational study using existing data, not a controlled trial, so results may be influenced by unmeasured factors. It does not test new treatments or vaccines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMMUNITY-ACQUIRED PNEUMONIA (CAP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer United States
New York, New York, 10017, United States